The stock is a binary clinical-stage biotech. The IND clearance and initiation of the Corventis trial are the primary value drivers. Monitor for first patient enrollment by end of 2026 and initial proof-of-concept data in H2 2027. The BMS partnership provides non-dilutive funding but the stock remains a high-risk pipeline story.
Price Chart
Executive Summary
Atrium Therapeutics reported Q2 2026 collaboration revenue of $3.0M, down 22% YoY from $3.8M, and a net loss of -$20.2M (-$1.18/share), widening from -$12.9M (-$0.75/share) in Q2 2025. The headline miss vs consensus is not directly comparable as the company is pre-revenue with lumpy milestone payments. The key positive is the FDA IND clearance for ATR 1072 and the second $15M BMS milestone (to be booked in Q3), extending cash runway through mid-2028. The stock will trade on the clinical catalyst timeline, not the quarterly financials.
Key Financial Metrics
Key Facts
- Collaboration revenue was $3.0M for Q2 2026, down from $3.8M in Q2 2025.
- Net loss widened to -$20.2M (-$1.18/share) from -$12.9M (-$0.75/share) in Q2 2025.
- FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial initiated for PRKAG2 syndrome.
- Second $15M milestone payment earned from BMS in August 2026 (to be recognized in Q3).
- Cash, equivalents, and short-term investments totaled $263.9M as of June 30, 2026, sufficient through mid-2028.
Financial Impact
Q2 2026 collaboration revenue $3.0M; net loss -$20.2M; cash $263.9M
Risk Factors
- Clinical trial enrollment delays or safety/efficacy failures for ATR 1072.
- Cash burn rate may accelerate as the pipeline expands, potentially requiring future dilutive financing.
- Lumpy collaboration revenue makes quarterly comparisons noisy and unpredictable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-349482 |
| Document: d149126d8k.htm | 0001193125-26-349482 |
| Document: 0001193125-26-349482-index-headers.html | 0001193125-26-349482 |
| Document: 0001193125-26-349482-index.html | 0001193125-26-349482 |
| Document: 0001193125-26-349482.txt | 0001193125-26-349482 |
| 8-K Data (Synthetic) | 0001193125-26-349482 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $8.20 | awaiting T+5 | — | $8.32 (+1.46%) |
Oct 20, 2026 6d ago | Press Release | $8.00 | awaiting T+5 | — | $8.32 (+4.00%) |
Oct 9, 2026 18d ago | 8-K/A | $8.40 $7.67 | ▼ −8.69% | ▼ −6.72% | $8.32 (−0.95%) |
Oct 8, 2026 19d ago | 8-K | $8.26 $7.82 | ▲ +5.33% | ▲ +5.05% | $8.32 (−0.73%) |
Sep 21, 2026 5w ago | Press Release | $9.22 $8.42 | ▼ −8.68% | ▼ −7.49% | $8.32 (−9.76%) |
Aug 20, 2026 9w ago | Press Release | $13.20 $13.64 | ▲ +3.33% | ▲ +2.86% | $8.32 (−36.97%) |
Aug 13, 2026 10w ago | 8-K | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.32 (−35.20%) |
Aug 13, 2026 10w ago | Press Release | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.32 (−35.20%) |
Jul 20, 2026 14w ago | Press Release | $12.29 $11.57 | ▼ −5.86% | ▼ −4.63% | $8.32 (−32.30%) |
Jul 14, 2026 14w ago | 8-K | $12.30 $12.17 | ▼ −1.06% | ▼ −0.08% | $8.32 (−32.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers